Ong, Sally S.
Hsu, S. Tammy
Grewal, Dilraj
Arevalo, J. Fernando
El-Dairi, Mays A.
Toth, Cynthia A.
Vajzovic, Lejla
Funding for this research was provided by:
International Association of Government Officials (iGO) Fund
Knights Templar Eye Foundation
Research to Prevent Blindness Unrestricted Grant to Duke Eye Center
NIH (RO1 EY25009)
NIH (P30 EY005722)
Heidelberg Engineering
Article History
Received: 23 June 2019
Revised: 13 October 2019
Accepted: 3 November 2019
First Online: 22 November 2019
Compliance with ethical standards
:
: DG has received research grants from Alimera Sciences and Allergan. JFA holds a patent from Springer SBM LLC; is a consultant for Turing Pharmaceuticals LLC, DORC International B.V., Allergan Inc., Bayer, and Mallinckrodt; and has received research grants from TOPCON. MAE has received research grants from the Knights Templar Eye Foundation. CAT receives royalties from Alcon and has received a research grant from NIH (RO1 EY25009). LV receives research grants from Janssen Pharmaceutical, Roche, DORC, Second Sight, Alcon, Genentech, B&L, and Alimera Sciences. STH declares that she has no conflict of interest. SSO declares that she has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Duke University and Johns Hopkins University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study from Duke University. One participant was retrospectively included from Johns Hopkins University and no consent was obtained from this single case report.
: Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. The sponsors or funding organizations had no role in the design or conduct of this research.